Global Initiative Launches Access to Essential Childhood Cancer Medicines

By João L. Carapinha

March 25, 2025

The World Health Organization (WHO) and St. Jude Children’s Research Hospital have launched a major effort to distribute essential childhood cancer medicines. This initiative is part of a new Global Platform targeting low- and middle-income countries (LMICs). It aims to deliver a consistent supply of quality-assured cancer drugs at no cost. The goal is to reach 50 countries within the next 5-7 years.

Current Progress and Reach

The platform is currently providing medicines to Mongolia and Uzbekistan. They also have planned shipments for Ecuador, Jordan, Nepal, and Zambia. The WHO and St. Jude Children’s Research Hospital expect to reach approximately 120,000 children diagnosed with cancer in low- and middle-income countries (LMICs). This marks the first large-scale effort of its kind, as they unite governments, the pharmaceutical industry, and NGOs to ensure consistent access to quality childhood cancer medicines.

Addressing Survival Disparities

Childhood cancer survival rates in low- and middle-income countries often fall below 30%. In high-income countries, rates exceed 80%. The WHO Global Initiative for Childhood Cancer, launched in 2018, aims to increase survival rates for six treatable cancers to 60% by 2030 in participating nations.

Potential for Transformative Change

This initiative could significantly advance health economics and outcomes research. It will improve data collection on childhood cancer treatment and outcomes in resource-limited settings. It may also reduce healthcare costs linked to inconsistent or inadequate cancer treatment. The platform’s strategy of consolidating demand for childhood cancer medicines could reshape pricing and procurement strategies for other vital drugs in low- and middle-income countries.

For further details on this essential initiative, you can explore the original article from the WHO.

Reference url

Recent Posts

Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Strategies

By HEOR Staff Writer

October 10, 2025

What are the most effective obesity prevention strategies for reducing long-term healthcare and societal costs in the United States? Recent advanced population models reveal that focusing on early, targeted obesity prevention strategies offers far greater value to health systems and society than ...
Simponi Pediatric Approval: FDA Grants First Pediatric Indication for Ulcerative Colitis Treatment

By HEOR Staff Writer

October 9, 2025

The U.S. Food and Drug Administration has granted Simponi pediatric approval for Johnson & Johnson's Simponi (golimumab), which is intended for children with moderately to severely active ulcerative colitis who weigh at least 15 kg. This historic approval is backed by data from the PURSUIT pr...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS
The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...